VRAX logo

Virax Biolabs Group Limited

VRAX
Healthcare|Biotechnology|GB
$0.79
-0.39 (-32.89%)
DCF Value
$14.60
Tangible Book / Share
$18.45
Cash / Share
$16.39

About

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.

Stock Price

-93.7%(1Y)
1M
-60.2%
3M
-73.4%
6M
-81.5%
YTD
-90.8%
1Y
-93.2%
3Y
-98.7%
5Y
-100.0%

Pipeline Summary

0 total trials
0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4

Key Facts

Market Cap$1.1M
Employees26
CEOJames Foster
IPO DateJul 21, 2022
Beta1.48
52-Week Range$0.63 – $21.75
Avg Volume1,450,474
ExchangeNASDAQ
Websiteviraxbiolabs.com

Ownership

Float1454.7%
Shares Outstanding1.3M

Recent Insider Trades

Monteil ClementOTHER
Oct 5, 202660 shares @ $310.00
Monteil ClementOTHER
Oct 5, 2026400 shares @ $150.00
Monteil ClementOTHER
Oct 5, 2026800 shares @ $17.00
Monteil ClementOTHER
Oct 5, 2026600 shares @ $21.90
Monteil ClementOTHER
Oct 5, 20263,000 shares @ $3.75

Peers

ARTLArtelo Biosciences, Inc.
$6.7M
ATXIAvenue Therapeutics, Inc.
$1.4M
DRMADermata Therapeutics, Inc.
$3.8M
ELABPMGC Holdings Inc.
$1.3M
GTBPGT Biopharma, Inc.
$5.6M
MLECMoolec Science S.A.
$617.2K
NCELNewcelX Ltd.
$1.2M
NKGNNKGen Biotech, Inc.
$1.4M

Recent News

Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China
Oct 29, 2026 · prnewswire.com
Virax Biolabs Group Limited (NASDAQ:VRAX) Sees Large Decline in Short Interest
Oct 12, 2026 · defenseworld.net
Data last updated: Nov 9, 2026, 04:39 AM